tb disease prevalence survey -overview, why and how...tb disease prevalence survey -overview, why...
TRANSCRIPT
![Page 1: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/1.jpg)
TB Disease Prevalence Survey
- Overview, why and how
Ikushi Onozaki MD, MPH
Team Leader, TB Prevalence Survey
WHO Global Task Force on TB Impact
Measurement
Stop TB Department, WHO
![Page 2: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/2.jpg)
3 strategic areas of work of the Task
Force� Strengthening surveillance - use of
routine surveillance data to measure incidence, prevalence and mortality� all countries
� ultimate goal to measure cases and deaths directly from notification and vital registration directly from notification and vital registration data
� Prevalence of TB disease surveys in ≥ 21 global focus countries
� Periodic review and revision of methodsused to translate data from surveillance systems and surveys into estimates of disease burden
![Page 3: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/3.jpg)
� TB prevalence is an MDG indicator that can be directly measured
� Estimation of TB disease burden using tuberculin surveys (standard method in 1990
TB Prevalence survey
tuberculin surveys (standard method in 1990 estimate by WB and WHO) no longer applicable
�Funding is available for surveys, and governments and international agencies recognize importance of measuring impact
![Page 4: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/4.jpg)
� Country – Eager to know real situation of TB in community
�If over-estimate: can't escape from criticism that your efforts are not enough�If under-estimate: No additional
Why TB Prevalence survey
�If under-estimate: No additional investment after achieving the targets - > TB can't be controlled; patients get the problem
�Donors and global community – Eager to know the impact of efforts on TB epidemiology
![Page 5: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/5.jpg)
� To know TB burden in a country
� To measure the change/impact
TB Prevalence survey
� To measure the change/impact
(new)�To know limitation of the current programme to improve the programme/ to revise the strategy
![Page 6: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/6.jpg)
� Prevalence of Bacteriologically Confirmed Pulmonary TB disease among adult population in community
�Often aged 15 years old or more
What we are measuring
As TB is a "rare" disease, a sample size of 30,000-60,000 is often necessary to have a good estimate
(will be discussed by Babis)
![Page 7: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/7.jpg)
Recent National Surveys with CXR screening and culture
with Notification Data by routine surveillance
/100,000 Notification rate Prevalence
S+ New All TB SS + Bac+ Pul.
Cambodia
2002
125 178 269 898
Philippines
2007
98 160 200 490
Viet Nam
2007
62 111 145 224
Myanmar
2009
83 257 170 434
Conservative point estimates assuming that there is no bacteriologically+ case in children
![Page 8: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/8.jpg)
� TB incidence can't be estimated directly from prevalence� Hard to estimate the TB burden in Children and the burden of Extrapulmonary TB by a community survey
Limitations
community survey� Sub-national estimations more than a few strata require a huge sample size�A survey is costly and labour intensive�Under/Over estimation due to limitations in screening and diagnostic tools
![Page 9: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/9.jpg)
� Unclear TB burden and trend from surveillance data (unreliable or incomplete surveillance)� High TB prevalence� High TB/HIV prevalence
Where we recommend a survey
� High TB/HIV prevalence� Previous study to compare---------------------------------------------� TB service to cope with the findings� Willingness of Country
Mostly countries approached us to consult or proposed survey without consultation
![Page 10: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/10.jpg)
Countries where surveys are recommended (Approved by Task Force Meeting, Dec 2007)
21 global focus countries
36 additional countries that met basic criteria
Note: Ethiopia was added to the global focus countries in 2009
![Page 11: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/11.jpg)
�Set a global guidance for standardization
�Assist Countries
�Feasibility assessment
�Preparation & in-country sensitization
�Workshops: Study design & Budgeting
�Protocol Review
Global Task Force
�Protocol Review
�Coordination of Technical Assistance
�Survey Operation Review
�Analysis
�Certificate the study
�Training (Survey managers, Consultants)
�Provide data for Re-estimation of TB Burden
�Global Advocacy & Fund raising
![Page 12: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/12.jpg)
Requirements (1) Chapter 2
• Strong commitment and leadership from the NTP/Ministry of Health and a core group of professionals;
• Identification of a suitable institute, organization or agency to lead and organization or agency to lead and manage survey implementation;
• Adequate laboratory capacity;
• Pre-Approval of survey methods for chest X-ray screening by the National Radiation Authority;
![Page 13: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/13.jpg)
Requirements (2)
• Reliable and timely support for procurement and logistics;
• Funding;
• Field security;• Field security;
• Community participation;
• Clearance of survey protocols by national and international review boards; and
• The availability of external support and technical assistance.
![Page 14: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/14.jpg)
We also need
• Full time survey coordinator or project leader from the early stage of the preparation
• Leading technical assistance agency or consultant
![Page 15: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/15.jpg)
Current status of survey
implementationimplementation
![Page 16: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/16.jpg)
Good Progress in Asia• China: 1990-2000-2010 Completed• Philippines: 1987-1997-2007-(2013/14)
• Cambodia: 2002-2011 Ongoing• Viet Nam: 2007-(2013/14)
• Indonesia: 2004- (2013/14)
• Thailand: 1991- (2006)-2011 From July• Thailand: 1991- (2006)-2011 From July• Bangladesh: 2008- (by 2015)
• Myanmar: 1994-2009/10 Completed• Pakistan: 1987- 2011 Ongoing-------------------------------------------------------------• Malaysia: 2003
• Laos: 2010/11 Ongoing
![Page 17: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/17.jpg)
No survey in Africa started yet since 2007 meeting
– urgent action required!!
(STB Department meeting, (STB Department meeting, 15 September 2010)
![Page 18: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/18.jpg)
Ethiopia Launched
National TB Prevalence Survey
BREAKING NEWS 3 OCT 2010
![Page 19: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/19.jpg)
Viet Nam
Uganda
Tanzania Philippines
Bangladesh
Thailand
5
6
7
8
Nu
mb
er
of
su
rve
ys
21 Global Focus
countries identified
by Task Force
Global progress, prevalence surveys
Pakistan
Cambodia PhilippinesThailandEritreaIndonesiaMalaysia Bangladesh MyanmarCambodia Ghana Kenya
Viet Nam China Nigeria Malawi Indonesia
The Gambia
Lao PDR
Ethiopia Rwanda MozambiqueZambia
S. Africa Nepal
Tanzania Philippines
0
1
2
3
4
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013-
15
Nu
mb
er
of
su
rve
ys
Asia Africa Non Global Focus country
Pakistan
![Page 20: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/20.jpg)
Task Force
Major recommendationsMajor recommendations
![Page 21: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/21.jpg)
How should surveys be implemented?
Follow the Follow the guidelines!
7000 copies Sold OUT
![Page 22: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/22.jpg)
2nd edition of Handbook –
launched in Berlin, 15 November
Major collaborative effort January–November 2010January–November 2010
46 authors
Multiple agencies/ universities/research institutes and NTPs
Funding from USAID, DGIS, Japan
You got first copies today
![Page 23: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/23.jpg)
�Population proportionate cluster samplings
�Stratification (e.g. geographical areas or
urban/rural)
For sampling efficiency
Not pursuing prevalence of subset population
�Smaller cluster size: <1,000 (500-700)/cluster
Sample size and Sampling
�Smaller cluster size: <1,000 (500-700)/cluster
�Prevalence Assumption: WHO estimate
(Conservative side) or estimate from sub-
national/previous studies
�Relative precision: 20-25%
�Design (Cluster) effect: 1.5 - 2.0 or more (k= 0.4-
0.6)
�Minimum Participation rate: => 85%
![Page 24: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/24.jpg)
How to select households/individuals within a selected sampling unit
� Random sampling of individuals or households is often not feasible
� Often unclear in � Often unclear in most protocols� Starting from the
centre may have a potential bias
� Need clear SOP and guidance
![Page 25: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/25.jpg)
Recommended screening strategy
Do smear and culture at least for with TB symptoms and/or abnormal chest X-ray
![Page 26: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/26.jpg)
( WHO headquarters, March 2008)
![Page 27: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/27.jpg)
Quality indicators
• Study coverage (exclusion due to insecurity…)
• Eligibility
• Participation (screening)
• Eligible for further examinations (lab)• Eligible for further examinations (lab)
• Sputum collection
• Examination process (recovery, contamination …)
• Data entry (missing values; should be corrected)
![Page 28: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/28.jpg)
Complexity of data management
FROM SOP of CAMBOIDA SURVEY 2011
![Page 29: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/29.jpg)
A carefully designed survey can tell
you lots more than TB prevalence
• Changes in TB burden and re-estimation of burden
• Performance of strategies for screening of TB suspects
• Health-seeking behaviour of TB patients and individuals reporting chest symptoms
• Where and why are cases missed by the NTP e.g. access to care, role of private sector
• Risk factors
![Page 30: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/30.jpg)
Interviews
Which interviews you will carry out, or all?
• S/E question during the census:
• Screening interview to all the participants: 100%
• In depth interview to TB symptpmatics: 5% ?• In depth interview to TB symptpmatics: 5% ?
• In depth interview to TB on Tx: <100
• In depth interview to detected TB patients: 100-
300 (with contact investigation to children)?
![Page 31: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/31.jpg)
Where are cases being missed?
64 participants were on TB treatment
9%
5%
Yangon survey, 2006: 1/3 of TB patients being treated by GPs
52%
34%
NTP 33
GP 22
Other 6
Unknown 3
33 in NTP: around 130/100,000 = 260/100,000/year
![Page 32: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/32.jpg)
Why Chest Radiogram and
Culture are important Culture are important
![Page 33: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/33.jpg)
Recent National Surveys with CXR screening and culture
with Notification Data by routine surveillance
/100,000 Notification rate Prevalence
S+ New All TB SS + Bac+ Pul.
Cambodia
2002
125 178 269 898
Philippines
2007
98 160 200 490
Viet Nam
2007
62 111 145 224
Myanmar
2009
83 257 170 434
Conservative point estimates assuming that there is no bacteriologically+ case in children
![Page 34: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/34.jpg)
Strategies for screening TB suspects
No Chronic Cough No symptom
S+ Bac + Bac +
Cambodia 38% 61% 15%
40-60% of confirmed cases in surveys do not have chronic cough
Cambodia 38% 61% 15%
Zambia 57% 10%
Viet Nam 40% 45% 25%
NTP Cambodia. National TB Prevalence Survey Report, 2002. 2005, ** H Ayles et al. Plos one May 2009. e 5602, *** NTP Viet Nam. Presented in UNION APR Conference, Beijing, Sept 2009
![Page 35: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/35.jpg)
Myanmar National Survey 2009/10Among
Partici-
pants
Proportion
in SS+
subjects
Proportion
in Bac +
Chronic cough
(2w)
4% 41% 25%
Cough any 24% 72% 51%Cough any
duration
24% 72% 51%
Any symptom 37% 79% 62%
CXR TB susp 5 % 79% 73%
CXR any
abnormality in
lung
12 % 95% 92%
![Page 36: TB Disease Prevalence Survey -Overview, why and how...TB Disease Prevalence Survey -Overview, why and how Ikushi Onozaki MD, MPH Team Leader, TB Prevalence Survey WHO Global Task Force](https://reader036.vdocuments.site/reader036/viewer/2022071215/60456f3d4ebcda01af7daf49/html5/thumbnails/36.jpg)
Bottlenecks of the operation
• CXR and Interview � 150-200/day (-300)
• If 10-15% need to submit specimens
� 15-30 persons/ day = 30-60 specimens/ day
• If there is a transportation every two days• If there is a transportation every two days
� 60-120 specimens/
• If 3 clusters operate at one time
� Lab will receive 200-300 specimens in a day
Careful planning is essential